Scientists identify new target for melanoma immunotherapy

Scientists identify new target for melanoma immunotherapy
Melanoma tumour cells expressing CD155. Credit: QIMR Berghofer

QIMR Berghofer research has found a new reason why some melanoma patients do not respond well to immunotherapy—a discovery that could lead to better-tailored treatments for the potentially deadly cancer.

Australia has the highest rate of melanoma in the world. The Australian Institute of Health and Welfare estimates there were more than 15,000 cases of melanoma in Australia last year, and more than 1700 deaths.

The research, led by QIMR Berghofer Senior Scientist and Immunology Department Coordinator Professor Mark Smyth, found high levels of the protein CD155 in human melanoma cells made the skin cancer harder to treat with immunotherapy.

"Our study has highlighted the central importance of CD155 to the effectiveness of immunotherapy for patients with metastatic melanoma—something that hasn't been shown before in humans," Professor Smyth said.

"The tumor appears to be using the CD155 molecule to escape being hunted down by immune cells, called T-cells, and to also resist being killed off by immunotherapy."

The CD155 protein is expressed by nearly all and less so by normal cells, including some immune cells. It is part of a family of adhesive proteins that are important in cell to cell interaction.

"Modern immunotherapy treatments have been quite successful in helping unleash our immune systems to kill melanoma tumor cells, but in some people the tumor cells remain disguised and treatments don't work, often leading to death," Professor Smyth said.

"We found high levels of CD155 in melanoma cells seem to help tumors evade detection by the T-cells and trick them into leaving the tumor alone. The tumor CD155 appears to wound the T-cells during the interaction, reducing their capacity to subsequently recognize and kill tumor cells. Reducing tumor CD155 in people with may be a way to improve the effectiveness of immunotherapy for them and save the lives of many more people."

The researchers used new imaging technology to examine pre-treatment tumor samples collected from patients in Brisbane, Sydney and Italy and correlated the levels of CD155 with the patients' survival outcomes.

Contributing author and Royal Brisbane and Women's Hospital Medical Oncologist, Dr. Elizabeth Ahern, said the imaging showed very high levels of CD155 in melanoma cells.

"We found patients with higher levels of the had worse health outcomes and didn't respond well to immunotherapies," Dr. Ahern said.

"It's the quantity of CD155 proteins that makes it so immune evasive. It appears the T-cells can't kill the tumor because the CD155 proteins are unbalancing the T- and turning them off before they can do their job. Currently there are no therapeutics used for that target CD155, so we hope to explore that pathway. We now want to focus on designing new immunotherapies that target the CD155 proteins to get them off the tumor."

The study findings have been published in the journal Clinical Cancer Research.

The study builds on Professor Smyth's 2018 research that showed CD155 in both tumor and was important for tumor growth and spread.

Professor Smyth and his team hope to expand the study to examine if CD155 plays a role in how other cancers respond to immunotherapies.

Explore further

Tumor vs. immune system: A battle to decide the host's fate

More information: Ailin Lepletier et al. Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma, Clinical Cancer Research (2020). DOI: 10.1158/1078-0432.CCR-19-3925
Journal information: Clinical Cancer Research

Provided by QIMR Berghofer Medical Research Institute
Citation: Scientists identify new target for melanoma immunotherapy (2020, June 30) retrieved 19 June 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments